Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Valeant Pharmaceuticals Intl (VRX)

Valeant Pharmaceuticals Intl (VRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Valeant Pharmaceuticals Intl 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 CAN

www.valeant.com P: 514-744-6792

Description:

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Key Statistics

Overview:

Market Capitalization, $K 8,159,814
Shares Outstanding, K 348,710
Annual Sales, $ 8,724 M
Annual Net Income, $ 2,404 M
Last Quarter Sales, $ 1,995 M
Last Quarter Net Income, $ -2,693 M
60-Month Beta -0.38
% of Insider Shareholders 5.87%
% of Institutional Shareholders 46.95%

Growth:

1-Year Return 35.34%
3-Year Return -90.09%
5-Year Return -74.23%
5-Year Revenue Growth 145.98%
5-Year Earnings Growth -12.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.89 on 05/08/18
Latest Earnings Date 08/14/18
Earnings Per Share ttm 3.96
EPS Growth vs. Prev Qtr -9.18%
EPS Growth vs. Prev Year -68.21%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Most Recent Dividend 1.000 on 11/10/10
Dividend Payable Date 12/22/10
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 10/16/00

VRX Ratios

Ratio
Price/Earnings ttm 6.12
Price/Earnings forward 6.96
Price/Earnings to Growth 0.35
Return-on-Equity % 27.87%
Return-on-Assets % 3.58%
Profit Margin % 27.56%
Debt/Equity 4.25
Price/Sales 0.97
Price/Cash Flow 1.87
Price/Book 1.80
Book Value/Share 12.97
Interest Coverage 0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar